Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VLA15 Lyme Disease Vaccine in Healthy Adults
NCT03769194Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of VLA15 in Lyme disease (4 arms), sponsored by Pfizer. Primary endpoint: Geometric Mean Titers for IgG Against Each OspA Serotype ST1 to ST6 at Day 85. Started Dec 2018; status: completed.
02
Drugs
VLA15
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT03769194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769194.